INT156130

From wiki-pain
Revision as of 04:11, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 29
Total Number 29
Disease Relevance 26.16
Pain Relevance 2.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPING1) extracellular region (SERPING1)
Anatomy Link Frequency
Plasma 3
SERPING1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 79 98.08 Very High Very High Very High
bradykinin 281 97.64 Very High Very High Very High
Pain 85 97.34 Very High Very High Very High
abdominal pain 33 96.64 Very High Very High Very High
cva 3 96.16 Very High Very High Very High
Inflammation 17 94.68 High High
b2 receptor 26 89.68 High High
headache 18 59.20 Quite High
depression 14 58.80 Quite High
nud 2 51.36 Quite High
Disease Link Frequency Relevance Heat
Hereditary Angioedema 1299 100.00 Very High Very High Very High
Lymphatic System Cancer 17 100.00 Very High Very High Very High
Lymphoproliferative Disease 7 100.00 Very High Very High Very High
Paraproteinemias 1 100.00 Very High Very High Very High
Pressure And Volume Under Development 612 99.98 Very High Very High Very High
Disease 127 99.98 Very High Very High Very High
Postoperative Complications 1 99.98 Very High Very High Very High
Renal Disease 21 99.80 Very High Very High Very High
Membranous Glomerulonephritis 51 99.76 Very High Very High Very High
Edema 164 99.70 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Treatment at the time of prodromal symptoms, which may result in occasional over treatment, but which will still conserve concentrate and reduce cost when compared to prophylactic therapy, would decrease morbidity and mortality associated with HAE.
HAE Binding (associated) of associated with hereditary angioedema
1) Confidence 0.42 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 0.84 Pain Relevance 0.10
However, identifying potential patients who would benefit from a long-term prophylaxis regimen is imperative to decrease the morbidity and mortality associated with HAE.
HAE Binding (associated) of associated with hereditary angioedema
2) Confidence 0.42 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 0.37 Pain Relevance 0.03
Because of the significant morbidity and mortality associated with HAE, careful management of these patients is essential.
HAE Binding (associated) of associated with hereditary angioedema
3) Confidence 0.40 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 1.55 Pain Relevance 0
Differences in disease severity, manifestation, or clinical course have not been associated with HAE type, but both types are associated with a deficiency in functional C1-inhibitor [2,3].


HAE Binding (associated) of associated with hereditary angioedema and disease
4) Confidence 0.38 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.55 Pain Relevance 0
FFP has also been used, but does present increased risk for viral transmission as compared with C1-inh, and there have been anecdotal reports of exacerbations of an acute attack when FFP is given for treatment; however, it appears this is a very infrequent occurrence [6].
C1-inh Binding (compared) of
5) Confidence 0.37 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 0.38 Pain Relevance 0.16
Anti-C1-INH autoantibodies recognize epitopes around the reactive center of C1-INH and by binding these epitopes render the protein functionally inactive and/or increase its catabolism [18,19].
C1-INH Binding (binding) of
6) Confidence 0.37 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.73 Pain Relevance 0
One such product is a recombinant human C1-INH (rhC1-INH) (Rhucin®; Pharming, Leiden, The Netherlands).
C1-INH Binding (recombinant) of
7) Confidence 0.36 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.70 Pain Relevance 0
Recombinant human C1INH
C1INH Binding (Recombinant) of
8) Confidence 0.36 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.71 Pain Relevance 0
C1-inhibitor replacement therapy addresses the primary cause of HAE by replacing C1-inhibitor.
C1-inhibitor Binding (replacing) of associated with hereditary angioedema
9) Confidence 0.34 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.91 Pain Relevance 0.12
In persons with a mutation associated with C1-inhibitor deficiency, angioedema attacks may occur spontaneously even in the absence of an overt precipitating factor.
C1-inhibitor Binding (associated) of associated with pressure and volume under development
10) Confidence 0.34 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 1.25 Pain Relevance 0.11
Because the subcutaneous edema associated with HAE is often painless, and because subcutaneous injections of bradykinin are acutely painful, investigators initially believed that a complement-derived permeability factor would be the most likely mediator of the angioedema associated with C1-inhibitor deficiency [2,20].
C1-inhibitor Binding (associated) of associated with pain, pressure and volume under development, hereditary angioedema and bradykinin
11) Confidence 0.34 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.71 Pain Relevance 0.28
This is important, since failure to access emergency treatment in a timely manner is the major contributor to the employment, educational and social difficulties associated with HAE, as well as to mortality.
HAE Binding (associated) of associated with hereditary angioedema and emergencies
12) Confidence 0.33 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.46 Pain Relevance 0.06
Increased levels of vascular permeability factors associated with C1-inhibitor deficiency may result in sudden local diminishments of endothelial barrier function.
C1-inhibitor Binding (associated) of
13) Confidence 0.33 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.66 Pain Relevance 0.06
Subnormal levels of C1-inhibitor are associated with the inappropriate activation of a number of pathways – including, in particular, the complement and contact systems, and to some extent, the fibrinolysis and coagulation systems.
C1-inhibitor Binding (associated) of
14) Confidence 0.33 Published 2008 Journal Clin Mol Allergy Section Abstract Doc Link PMC2374835 Disease Relevance 1.00 Pain Relevance 0.26
In addition to androgen therapy, other medications have been investigated as prophylactic agents for HAE.
HAE Binding (agents) of associated with hereditary angioedema
15) Confidence 0.33 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 1.25 Pain Relevance 0.19
Antifibrinolytics, such as epsilon-aminocaproic acid, has also been used as a prophylactic agent for HAE.
HAE Binding (agent) of associated with hereditary angioedema
16) Confidence 0.33 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 1.07 Pain Relevance 0.12
Anti-C1-INH autoantibodies recognize epitopes around the reactive center of C1-INH and by binding these epitopes render the protein functionally inactive and/or increase its catabolism [18,19].
Anti-C1-INH Binding (binding) of
17) Confidence 0.32 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.83 Pain Relevance 0
Plasma-derived C1-INH - PdC1INH
PdC1INH Binding (Plasma) of in Plasma
18) Confidence 0.32 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 0.06 Pain Relevance 0
Plasma-derived C1 inhibitor - pdC1INH
pdC1INH Binding (Plasma) of in Plasma
19) Confidence 0.32 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 1.03 Pain Relevance 0.07
AAE is frequently associated with lymphoproliferative diseases ranging from monoclonal gammopathies of uncertain significance (MGUS) to non-Hodgkin's lymphoma (NHL) and/or anti-C1-INH inactivating autoantibodies.
anti-C1-INH Binding (associated) of associated with lymphatic system cancer, paraproteinemias, lymphoproliferative disease and edema
20) Confidence 0.32 Published 2008 Journal Autoimmun Rev Section Abstract Doc Link 19014872 Disease Relevance 1.60 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox